Vioxx: lessons for Health Canada and the FDA.

Governing Collaborative Healthcare Improvement: Lessons From an Atlantic Canadian Case

The Atlantic Healthcare Collaboration for Innovation and Improvement in Chronic Disease (AHC) Quality Improvement Collaborative (QIC) in Eastern Canada provided an approach to spur system-level reform across multiple health systems for patients and families living with chronic disease. Developed and led by senior executives with a unique governance approach and involving clinical front-line tea...

Lessons From Zika Policies to Improve Gender Equity

Gender equity is easily supported in theory but harder to pursue in practice. In this article, the case of Zika travel policies is used to illustrate some glaring gaps related to gender, for both men and women, at both international and national levels. Zika travel policies have not considered new evidence on biological or social determinants of health, putting babies at risk of exposure. The a...

Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.

Worldwide drug withdrawal puts FDA under scrutiny Merck faces 300 lawsuits Karen

Vioxx is a cyclooxygenase (COX)-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by the USA’s Food and Drug Administration (FDA) in May 1999 for the relief of the signs and symptoms of osteoarthritis, the management of acute pain in adults, and the treatment of menstrual symptoms. Vioxx was later also approved for the relief of signs and symptoms of rheumatoid arthrit...

Vioxx, the implosion of Merck, and aftershocks at the FDA.